Compare Dollar General Corp. (DG) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Ginkgo Bioworks Holdings Inc — how do they compare? Dollar General Corp. trades at $127.32 (market cap $27.42B), while Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M). The key difference: Dollar General Corp. is far larger — about 35.9× Ginkgo Bioworks Holdings Inc's market cap, and Dollar General Corp. pays a 1.9% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Ginkgo Bioworks Holdings Inc for 7 Days on average.
| DG | DNA | |
|---|---|---|
Market Cap | $27.42B | $763.64M |
Volume | 2,291,517 | 3,204,177 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $15.83 |
52-Week Low | $95.94 | $5.48 |
Typical Hold Time | 59 Days | 7 Days |
Enterprise Value | $41.60B | $865.59M |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $126.16, up 3.27% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows solid fundamentals with a P/E of 16.14 and ROE of 19.69%, supported by positive cash flow trends and a growing revenue base. Recent news highlights strategic initiatives like tariff refunds, delivery expansion with Instacart, and the DG Media Network, enhancing its value-retail positioning.
The outlook for DG is positive, driven by earnings momentum and analyst consensus pointing to a $137.27 price target. Key opportunities include margin expansion from cost initiatives and digital growth, while risks involve competitive pressures and consumer spending sensitivity. The stock presents a compelling case for value investors seeking steady growth in the discount retail sector.
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
